Elite Pharmaceuticals, Inc. has scheduled the release of its second‑quarter 2026 fiscal year financial results for Friday, November 14, 2025, and will host a live conference call on Monday, November 17, 2025, at 11:30 AM Eastern Time.
The company’s most recent quarter, Q1 2026, ended June 30, 2025, and saw revenue climb 114% year‑over‑year to $40.2 million, while operating profit surged 462% to $21.7 million. In comparison, Q2 2025, which ended September 30, 2024, generated $18.9 million in revenue and $3.5 million in operating profit, underscoring the rapid acceleration in the company’s top‑line and bottom‑line growth.
Growth has been driven largely by the Elite label product line and the launch of lisdexamfetamine, which together have expanded the company’s market share in the specialty generic segment. Gross profit margin for Q1 2026 reached 68%, a substantial lift from 45% in the same quarter a year earlier, reflecting higher‑margin product mix and improved operational leverage.
CEO Nasrat Hakim emphasized confidence in the company’s growth trajectory, noting that the recent product launches have positioned Elite Pharmaceuticals for continued expansion. CFO Carter Ward highlighted the company’s disciplined cost management, which has helped sustain profitability even as revenue volumes increase. Management also cautioned that intense competition in the generic market could pressure margins in future quarters.
Analyst coverage of Elite Pharmaceuticals remains limited, with some analysts pointing to profitability concerns and cash‑flow inconsistencies. Despite the strong growth metrics, the company’s valuation multiples are considered unattractive by certain market observers, reflecting the broader competitive pressures in the generic pharmaceutical space.
With the earnings release and conference call scheduled, investors will gain insight into how the company’s recent product launches and cost‑control initiatives translate into financial performance, and whether the company can sustain its rapid growth trajectory amid competitive headwinds.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.